PGI, Chandigarh develops TrueOxy HFNC device for non-invasive ventilation

The Anaesthesia Department of the PGIMER has developed TrueOxy+ High Flow Nasal Cannula (HFNC) device, a cost-effective solution for non-invasive ventilation. This indigenous device boasts of an automatic airflow temperature oxygen control system, ensuring precise patient care.

The project was developed under Prof Goverdhan Dutt Puri, former Head of the Department of Anaesthesia.

High flow nasal cannula device

• TrueOxy+ delivers precise blend of air and oxygen, ensuring optimal oxygenation levels
• Beneficial in managing acute hypoxemic respiratory failure, post-surgical respiratory failure
• Doesn’t require invasive intubation; patients often find HFNC therapy more comfortable

With a focus on versatility, TrueOxy+ operates in a dual mode – airline and blower — catering to both adult and paediatric patients. The incorporation of advanced safety features, along with easy device and patient access, distinguishes it in the medical landscape.

The TrueOxy+ device delivers a precise blend of air and oxygen, ensuring optimal oxygenation levels. This can be particularly beneficial in managing acute hypoxemic respiratory failure, post-surgical respiratory failure and other conditions without resorting to invasive intubation. Patients often find HFNC therapy more comfortable than intubation. The high flow of warm and humidified oxygen enhances patient tolerance, potentially reducing the reluctance or discomfort associated with traditional ventilation methods. The HFNC therapy has shown promise in managing obstructive sleep apnea, providing a non-invasive option for patients with this condition.

With a focus on versatility, TrueOxy+ operates in a dual mode – airline and blower — catering to both adult and paediatric patients. The incorporation of advanced safety features, along with easy device and patient access, distinguishes it in the medical landscape.

The TrueOxy+ device delivers a precise blend of air and oxygen, ensuring optimal oxygenation levels. This can be particularly beneficial in managing acute hypoxemic respiratory failure, post-surgical respiratory failure and other conditions without resorting to invasive intubation. Patients often find HFNC therapy more comfortable than intubation. The high flow of warm and humidified oxygen enhances patient tolerance, potentially reducing the reluctance or discomfort associated with traditional ventilation methods. The HFNC therapy has shown promise in managing obstructive sleep apnea, providing a non-invasive option for patients with this condition. Tribune India